| Dr Kate Ann Markey, MBBS, PHD | |
|
825 Eastlake Ave E, Seattle, WA 98109-4405 | |
| (206) 520-5000 | |
| Not Available |
| Full Name | Dr Kate Ann Markey |
|---|---|
| Gender | Female |
| Speciality | Hematology/oncology |
| Experience | 14 Years |
| Location | 825 Eastlake Ave E, Seattle, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174088298 | NPI | - | NPPES |
| 1174088298 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | TR61203439 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Washington Medical Ctr | Seattle, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Association Of University Physicians | 0446162697 | 3009 |
News Archive
IRIDEX Corporation today announced the receipt of an Issue Notification from the U.S. Patent and Trademark Office for U.S. Patent No. 7,766,904, "Adjustable Laser Probe For Use In Vitreoretinal Surgery." This patent applies to a number of consumable medical devices already in the IRIDEX product line, collectively identified and sold as Adjustable and Intuitive EndoProbe® laser handpieces.
EpiTherapeutics and Abbott today announced a collaboration agreement to develop new anti-cancer drugs by making small-molecule inhibitors against selected epigenetic oncology targets.
Researchers have decoded the genome of the strain of Chlamydia that causes the most severe, invasive form of the disease. Their study shows that, despite recent increases in invasive infections, the strain has remained virtually unchanged for 40 years.
Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with low survival rates, with newly diagnosed patients surviving a median of 14 months and recurrent patients surviving a median of only 3 to 9 months. New therapeutic targets and biomarkers for prognosis are urgently needed.
Unravelling the entire genetic code for each child who has been diagnosed with cancer can give a more accurate diagnosis or reveal new treatment options, according to research presented at the NCRI Festival. These are the results of a pilot study of the process known as whole genome sequencing.
› Verified 9 days ago
| Entity Name | The Association Of University Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023041159 PECOS PAC ID: 0446162697 Enrollment ID: O20031105000244 |
News Archive
IRIDEX Corporation today announced the receipt of an Issue Notification from the U.S. Patent and Trademark Office for U.S. Patent No. 7,766,904, "Adjustable Laser Probe For Use In Vitreoretinal Surgery." This patent applies to a number of consumable medical devices already in the IRIDEX product line, collectively identified and sold as Adjustable and Intuitive EndoProbe® laser handpieces.
EpiTherapeutics and Abbott today announced a collaboration agreement to develop new anti-cancer drugs by making small-molecule inhibitors against selected epigenetic oncology targets.
Researchers have decoded the genome of the strain of Chlamydia that causes the most severe, invasive form of the disease. Their study shows that, despite recent increases in invasive infections, the strain has remained virtually unchanged for 40 years.
Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with low survival rates, with newly diagnosed patients surviving a median of 14 months and recurrent patients surviving a median of only 3 to 9 months. New therapeutic targets and biomarkers for prognosis are urgently needed.
Unravelling the entire genetic code for each child who has been diagnosed with cancer can give a more accurate diagnosis or reveal new treatment options, according to research presented at the NCRI Festival. These are the results of a pilot study of the process known as whole genome sequencing.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kate Ann Markey, MBBS, PHD Po Box 50095, Seattle, WA 98145-5095 Ph: (206) 520-5700 | Dr Kate Ann Markey, MBBS, PHD 825 Eastlake Ave E, Seattle, WA 98109-4405 Ph: (206) 520-5000 |
News Archive
IRIDEX Corporation today announced the receipt of an Issue Notification from the U.S. Patent and Trademark Office for U.S. Patent No. 7,766,904, "Adjustable Laser Probe For Use In Vitreoretinal Surgery." This patent applies to a number of consumable medical devices already in the IRIDEX product line, collectively identified and sold as Adjustable and Intuitive EndoProbe® laser handpieces.
EpiTherapeutics and Abbott today announced a collaboration agreement to develop new anti-cancer drugs by making small-molecule inhibitors against selected epigenetic oncology targets.
Researchers have decoded the genome of the strain of Chlamydia that causes the most severe, invasive form of the disease. Their study shows that, despite recent increases in invasive infections, the strain has remained virtually unchanged for 40 years.
Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with low survival rates, with newly diagnosed patients surviving a median of 14 months and recurrent patients surviving a median of only 3 to 9 months. New therapeutic targets and biomarkers for prognosis are urgently needed.
Unravelling the entire genetic code for each child who has been diagnosed with cancer can give a more accurate diagnosis or reveal new treatment options, according to research presented at the NCRI Festival. These are the results of a pilot study of the process known as whole genome sequencing.
› Verified 9 days ago
Sandhya Ramanathan Panch, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 825 Eastlake Ave E, Seattle, WA 98109 Phone: 206-520-5000 | |
Stephen A Lopez, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 925 Seneca St, Seattle, WA 98101 Phone: 206-341-0860 | |
Dr. Susan Hunt, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: Uwmc Department Of Medicine, Box 356429, Seattle, WA 98195 Phone: 206-221-7993 Fax: 206-221-8732 | |
Timothy William Menza, MD, PHD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 325 9th Ave, Seattle, WA 98104 Phone: 206-520-5000 | |
Dr. Vinay Gupta, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1100 9th Ave, Seattle, WA 98101 Phone: 206-223-6980 Fax: 206-223-6982 | |
Dr. Maria Ann Corcorran, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1550 N 115th St, Seattle, WA 98133 Phone: 206-520-5000 | |
Vyshak Alva Venur, M.D Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 825 Eastlake Ave E, Seattle, WA 98109 Phone: 206-520-5700 |